Digital therapies have shown value in improving patient access and increasing engagement, but can they also drive an overall better standard of care? This panel will explore how digital medicine gives us the opportunity to move beyond merely treating the symptoms of a disease, and begin to manage patient care in new ways that allow individuals to be evaluated and treated holistically based on their specific condition.

• What is needed to enable the personalization of treatments based on the patient’s unique symptoms and conditions?
• How can digital therapeutics be designed to address early disease detection and individualization of care?
• What new opportunities do digital therapeutics provide us for supporting patients and their entire care circle?

The panelists will share examples and successes they have experienced, and discuss strategies for getting these new care innovations into the hands of patients.

Featured Speakers

Moderator: Anthony Luttenberger
SVP, Life Science Partnerships
Biofourmis

Anthony is a 30+ year life sciences industry veteran with a strong track record as a commercial leader and expert in best-in-class healthcare technology and data informatics. This success has been achieved by helping pharmaceutical, biotech and medical device customers leverage emerging technology and data driven insights to improve patient access, realize higher outcomes and sustained growth in the most cost-effective way possible.Prior to Biofourmis, Anthony has held senior level leadership roles in healthcare technology. Most recently he was Vice President for Cardinal Health Specialty Pharmaceutical Solutions where he led the Regulatory Sciences Practice with the FDA and the Data Insights & Engagement Solutions area in real-world evidence, outcomes research, data & advanced analytics. Prior to that he has held key senior roles with IQVIA, UnitedHealth Group’s i3 Pharma Informatics now Optum, and Symphony Health.

Panelists:

Sarah Ernst
Senior Director, Digital Strategy and Partnering
Sanofi

Sarah Ernst joins us from her current role as Senior Director of Digital Strategy and Partnering where she supports Sanofi’s digital ambitions to increase use and analysis of real-world data, to adopt cutting advanced analytics and artificial intelligence, to increase the use wearables in clinical studies, and to advance the adoption of digital technologies in science and medicine. Prior to her time on the Digital Strategy and Partnering team, Sarah led digital innovation for the Global Rare disease team, and built the first global program focused on using data to improve the rare disease patient diagnosis journey.Prior to joining Sanofi, Sarah worked on the partnerships team at PatientsLikeMe, and held roles at Imprivata and The Advisory Board Company. She is passionate about working to improve the quality of medicine and care that patients receive, expanding access to this care, and ensuring affordability of care. She completed her undergraduate degree in Neuroscience at The University of Pennsylvania, and received her graduate degree in Masters of Engineering Management at Tufts University.

David Caouette
Exec. Director, Head of Enabling Functions, Strategy & Operations
Pfizer

David Caouette joined Pfizer in 2001 as a neuroscientist and electrophysiologist in the Neuroscience & Pain Research Unit (NPRU) in Groton, CT. Throughout his Pfizer career, David has held positions of increasing responsibilities, including Sr. Manager leading the NPRU’s Portfolio, Strategy and Communications efforts, Director playing a key role in the WRD Strategy & Portfolio Solutions group, and Sr. Director leading Strategy and Operations for Project BlueSky and the Quantitative Medicine group in Cambridge, MA.David is currently Executive Director, Head of Enabling Functions, Strategy, Operations & the Pfizer Innovation Research (PfIRe) Lab in the Digital Sciences & Translational Imaging (DSTI) group at Pfizer. The PfIRe Lab is an instrumented clinical space enabling identification, testing and validation of novel wearable devices and sensors as potential digital endpoints before deploying them into large scale, multi-site clinical studies. This helps Pfizer make clinical trials more patient-centric, improve the decision-making process, and ultimately accelerate the delivery of new medicines to patients.David owns a B.Sc. in Microbiology and M.Sc. in Experimental Medicine from Laval University in Canada, as well as an MBA from the University of Rhode Island.

Orel Swenson, M.D
Medical Director, Digital Therapeutics
Biofourmis

Orel Swenson, M.D. is the Medical Director for Digital Therapeutics at Biofourmis. Prior to Biofourmis Dr. Swenson worked at Riverflow Growth Fund, a Virginia based venture capital fund. His preceding experience includes practice as an emergency medicine physician, including serving as an associate medical director and director of observation medicine. Additionally, Dr. Swenson has extensive entrepreneurial experience, including cofounding a freestanding emergency department, and he holds an MBA from Duke University.